Cars in leukemia: relapse with antigen-negative leukemia originating from a single B cell expressing the leukemia-targeting CAR

Simon Francis Lacey, Jun Xu, Marco Ruella, David M Barrett, Irina Kulikovskaya, David E Ambrose, Prachi R Patel, Tyler Reich, John Scholler, Farzana Nazimuddin, Joseph A Fraietta, Shannon L Maude, Saar I Gill, Bruce L Levine, Christopher L Nobles, Frederic D Bushman, Elena Orlando, Stephan A Grupp, Carl H June, Jan Joseph Melenhorst

2016-12-02

Abstract:T cells bearing a second-generation anti-CD19 chimeric antigen receptor (CAR) induce complete remission in >90% of patients with acute lymphoblastic leukemia (ALL) at our institution. However, disease may recur and we recently identified two molecular mechanisms of relapse (PMID: 26516065). We here present a novel mechanism of antigen-negative relapse in a pediatric ALL patient. A 21 year-old male patient was in third relapse at the time of enrollment onto our CTL019 trial (ClinicalTrials.Gov #NCT01626495). The patient achieved an MRD-negative complete remission 1 month after CTL019 infusion but relapsed nine months later. Quantitative PCR analysis of the transgene and flow cytometry for CAR19 protein analysis showed the expected expansion of the CART cells followed by log-normal decay following disease eradication. At relapse, however, the transgene copy numbers had increased without a …